{"id":1910,"date":"2016-05-09T10:47:36","date_gmt":"2016-05-09T08:47:36","guid":{"rendered":"https:\/\/colox.ch\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/"},"modified":"2018-03-09T12:06:38","modified_gmt":"2018-03-09T11:06:38","slug":"novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research","status":"publish","type":"post","link":"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/","title":{"rendered":"Novigenix publishes multi-center study of Colox\u00ae in Clinical Cancer Research"},"content":{"rendered":"<h2><strong>Data validate blood-based test\u2019s ability <\/strong><\/h2>\n<h2><strong>to detect colorectal cancer early and reliably<\/strong><\/h2>\n<p>LAUSANNE, Switzerland, May 9, 2015 \u2013 Novigenix SA today announced the publication of<br \/>\na clinical validation study of Colox in the highly ranked journal Clinical Cancer Research.<br \/>\nColox is a blood test based on a 29-gene host immune response panel in combination with<br \/>\ntumor biomarkers for the early detection of colorectal cancer (CRC).<br \/>\nThe study \u201cDevelopment and clinical validation of a blood test based on 29-gene expression<br \/>\nfor early detection of colorectal cancer\u201d was conducted across seven institutions in<br \/>\nSwitzerland, and was designed to validate Colox on three independent test sets of patients,<br \/>\nwho were followed up with colonoscopy to determine the clinical performance of the test<br \/>\n(sensitivity and specificity). The data show that Colox has a specificity of 92%, and a<br \/>\nsensitivity of 78% for CRC and respectively 92% and 52% for large adenomas. Professor<br \/>\nGian Dorta, MD, of the Department of Gastroenterology and Hepatology at the Centre<br \/>\nhospitalier universitaire vaudois (CHUV) was principal investigator of the study.<br \/>\nProfessor Curzio R\u00fcegg of the Department of Medicine, Faculty of Science, University of<br \/>\nFribourg, who was involved in the test\u2019s development, said: \u201cThe inconvenience of current<br \/>\nmethods to detect colorectal cancer results in low adoption and the majority of individuals at<br \/>\nrisk not being tested. Colox has all the hallmarks of an effective and convenient test for<br \/>\ncolorectal cancer that can reliably identify patients for referral to intervention by colonoscopy.<br \/>\nIn addition, because of its unique combination of host immune response with tumor-derived<br \/>\nmarkers, Colox has the ability to detect precursor lesions of colorectal cancer, making it a<br \/>\npromising ally in cancer prevention.\u201d<br \/>\nBrian Hashemi, Executive Chairman of Novigenix SA, said: \u201cThe publication of our study in<br \/>\nClinical Cancer Research provides important validation of the clinical significance of Colox.<br \/>\nAs a convenient, and accurate blood test, Colox outperforms other commercially available<br \/>\nCRC blood tests, and has the potential to become truly instrumental in the reduction of<br \/>\ncancer mortality through early detection of advanced polyps and colorectal cancer. At<br \/>\nNovigenix we are committed to reducing cancer mortality, and every day we work with<br \/>\nclinicians and the healthcare community at large to broaden access to Colox in Switzerland<br \/>\nand abroad.\u201d<br \/>\nThe publication can be accessed here:<br \/>\n<a href=\"http:\/\/clincancerres.aacrjournals.org\/content\/early\/2016\/04\/28\/1078-0432.CCR-15-2057\">http:\/\/clincancerres.aacrjournals.org\/content\/early\/2016\/04\/28\/1078-0432.CCR-15-2057<\/a><\/p>\n<h4><strong>About colorectal cancer\u00a0<\/strong><\/h4>\n<p>Colorectal cancer is the second leading cause of cancer mortality in Europe and North<br \/>\nAmerica. Current methods of detection of CRC are cumbersome and invasive, requiring<br \/>\nunpleasant preparation of the colon, or stool manipulation at home. As a result the majority of<br \/>\nindividuals at average risk resist testing and fail to be referred to potentially therapeutic or<br \/>\npreventative colonoscopy. In Switzerland alone this leads to 1400 people dying per year from<br \/>\nthis largely preventable disease.<br \/>\nSylvain Monnier-Benoit, Ph.D.<br \/>\nProject Leader &amp; Founder<br \/>\nBiop\u00f4le IV<br \/>\nRoute de la Corniche 3<br \/>\nCH-1066 Epalinges<br \/>\nSwitzerland<br \/>\nsylvain.monnier-benoit@colox.ch<br \/>\n<a href=\"https:\/\/colox.ch\">www.novigenix.com<\/a><br \/>\nPhone +41 21 989 20 00<br \/>\nFax +41 21 989 20 01<\/p>\n<h3><strong>About <a href=\"https:\/\/colox.ch\/colox\">Colox\u00ae<\/a><\/strong><\/h3>\n<p>Colox\u00ae is a proven molecular blood test that has been designed to support physicians in case<br \/>\nfinding of patients with CRC and adenomas for referral to colonoscopy. The test can support<br \/>\nthe healthcare community to significantly reduce mortality from colorectal cancer through<br \/>\nearly detection and intervention. Colox can be ordered by any physician in routine medical<br \/>\npractice to identify patients with adenomatous polyps and colorectal cancer.<\/p>\n<h3><strong>About Novigenix SA:<\/strong><\/h3>\n<p>Novigenix SA is an innovative Swiss molecular diagnostics company focused on the<br \/>\ncommercialization of new blood tests for the early detection of cancer. Novigenix\u2019s products<br \/>\nrely on a new generation of predictive molecular signatures and state-of-the-art mathematical<br \/>\nanalytical models to provide new solutions for the early detection of cancer. For more<br \/>\ninformation please visit <a href=\"https:\/\/colox.ch\">www.novigenix.com<\/a><\/p>\n<p><em>Contact:<\/em><br \/>\nNovigenix SA Capricorn One (media)<br \/>\nNicolas Demierre Hans Herklots<br \/>\nnicolas.demierre@colox.ch capricorn1@bluewin.ch<br \/>\n+41 79 761 5184 +41 79 598 7149<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Data validate blood-based test\u2019s ability to detect colorectal cancer early and reliably LAUSANNE, Switzerland, May 9, 2015 \u2013 Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[],"class_list":["post-1910","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse-de"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novigenix publishes multi-center study of Colox\u00ae in Clinical Cancer Research - Colox<\/title>\n<meta name=\"description\" content=\"Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with tumor biomarkers for the early detection of colorectal cancer\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novigenix publishes multi-center study of Colox\u00ae in Clinical Cancer Research - Colox\" \/>\n<meta property=\"og:description\" content=\"Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with tumor biomarkers for the early detection of colorectal cancer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Colox\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/mymiddlelife\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-05-09T08:47:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-03-09T11:06:38+00:00\" \/>\n<meta name=\"author\" content=\"Novigenix\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Novigenix\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/\"},\"author\":{\"name\":\"Novigenix\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/person\/b62de2e3f97aea1ffe3303259cbbb20a\"},\"headline\":\"Novigenix publishes multi-center study of Colox\u00ae in Clinical Cancer Research\",\"datePublished\":\"2016-05-09T08:47:36+00:00\",\"dateModified\":\"2018-03-09T11:06:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/\"},\"wordCount\":640,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/colox.ch\/de\/#organization\"},\"articleSection\":[\"Communiqu\u00e9 de presse\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/\",\"url\":\"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/\",\"name\":\"Novigenix publishes multi-center study of Colox\u00ae in Clinical Cancer Research - Colox\",\"isPartOf\":{\"@id\":\"https:\/\/colox.ch\/de\/#website\"},\"datePublished\":\"2016-05-09T08:47:36+00:00\",\"dateModified\":\"2018-03-09T11:06:38+00:00\",\"description\":\"Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with tumor biomarkers for the early detection of colorectal cancer\",\"breadcrumb\":{\"@id\":\"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/colox.ch\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novigenix publishes multi-center study of Colox\u00ae in Clinical Cancer Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/colox.ch\/de\/#website\",\"url\":\"https:\/\/colox.ch\/de\/\",\"name\":\"Colox\",\"description\":\"The new generation blood test\",\"publisher\":{\"@id\":\"https:\/\/colox.ch\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/colox.ch\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/colox.ch\/de\/#organization\",\"name\":\"Novigenix SA\",\"url\":\"https:\/\/colox.ch\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"contentUrl\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"width\":700,\"height\":297,\"caption\":\"Novigenix SA\"},\"image\":{\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/person\/b62de2e3f97aea1ffe3303259cbbb20a\",\"name\":\"Novigenix\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/colox.ch\/wp-content\/uploads\/2017\/09\/Novigenix_avatar-96x96.png\",\"contentUrl\":\"https:\/\/colox.ch\/wp-content\/uploads\/2017\/09\/Novigenix_avatar-96x96.png\",\"caption\":\"Novigenix\"},\"description\":\"Novigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox\u00ae, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. Novigenix\u2019s technology is based on a new generation of predictive gene expression profiles of circulating blood cells and concentration profile of tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures of biomarkers provide new and accurate solutions for the early detection of cancer.\",\"sameAs\":[\"https:\/\/colox.ch\",\"https:\/\/www.facebook.com\/mymiddlelife\/\"],\"url\":\"https:\/\/colox.ch\/de\/author\/novigenix\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novigenix publishes multi-center study of Colox\u00ae in Clinical Cancer Research - Colox","description":"Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with tumor biomarkers for the early detection of colorectal cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/","og_locale":"de_DE","og_type":"article","og_title":"Novigenix publishes multi-center study of Colox\u00ae in Clinical Cancer Research - Colox","og_description":"Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with tumor biomarkers for the early detection of colorectal cancer","og_url":"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/","og_site_name":"Colox","article_author":"https:\/\/www.facebook.com\/mymiddlelife\/","article_published_time":"2016-05-09T08:47:36+00:00","article_modified_time":"2018-03-09T11:06:38+00:00","author":"Novigenix","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"Novigenix","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/#article","isPartOf":{"@id":"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/"},"author":{"name":"Novigenix","@id":"https:\/\/colox.ch\/de\/#\/schema\/person\/b62de2e3f97aea1ffe3303259cbbb20a"},"headline":"Novigenix publishes multi-center study of Colox\u00ae in Clinical Cancer Research","datePublished":"2016-05-09T08:47:36+00:00","dateModified":"2018-03-09T11:06:38+00:00","mainEntityOfPage":{"@id":"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/"},"wordCount":640,"commentCount":0,"publisher":{"@id":"https:\/\/colox.ch\/de\/#organization"},"articleSection":["Communiqu\u00e9 de presse"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/","url":"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/","name":"Novigenix publishes multi-center study of Colox\u00ae in Clinical Cancer Research - Colox","isPartOf":{"@id":"https:\/\/colox.ch\/de\/#website"},"datePublished":"2016-05-09T08:47:36+00:00","dateModified":"2018-03-09T11:06:38+00:00","description":"Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with tumor biomarkers for the early detection of colorectal cancer","breadcrumb":{"@id":"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/colox.ch\/de\/novigenix-publishes-multi-center-study-of-colox-in-clinical-cancer-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/colox.ch\/"},{"@type":"ListItem","position":2,"name":"Novigenix publishes multi-center study of Colox\u00ae in Clinical Cancer Research"}]},{"@type":"WebSite","@id":"https:\/\/colox.ch\/de\/#website","url":"https:\/\/colox.ch\/de\/","name":"Colox","description":"The new generation blood test","publisher":{"@id":"https:\/\/colox.ch\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/colox.ch\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/colox.ch\/de\/#organization","name":"Novigenix SA","url":"https:\/\/colox.ch\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/","url":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","contentUrl":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","width":700,"height":297,"caption":"Novigenix SA"},"image":{"@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/colox.ch\/de\/#\/schema\/person\/b62de2e3f97aea1ffe3303259cbbb20a","name":"Novigenix","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/colox.ch\/de\/#\/schema\/person\/image\/","url":"https:\/\/colox.ch\/wp-content\/uploads\/2017\/09\/Novigenix_avatar-96x96.png","contentUrl":"https:\/\/colox.ch\/wp-content\/uploads\/2017\/09\/Novigenix_avatar-96x96.png","caption":"Novigenix"},"description":"Novigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox\u00ae, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. Novigenix\u2019s technology is based on a new generation of predictive gene expression profiles of circulating blood cells and concentration profile of tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures of biomarkers provide new and accurate solutions for the early detection of cancer.","sameAs":["https:\/\/colox.ch","https:\/\/www.facebook.com\/mymiddlelife\/"],"url":"https:\/\/colox.ch\/de\/author\/novigenix\/"}]}},"_links":{"self":[{"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/posts\/1910"}],"collection":[{"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/comments?post=1910"}],"version-history":[{"count":0,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/posts\/1910\/revisions"}],"wp:attachment":[{"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/media?parent=1910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/categories?post=1910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/tags?post=1910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}